Silo Pharma (NASDAQ: SILO) announced a strategic expansion into artificial intelligence as a second line of business following its acquisition of assets from Qwikagents.ai, a platform designed to deploy autonomous AI agents for tasks including research, content generation, scheduling and workflow automation. The company said the move positions it to capitalize on a rapidly growing AI agent market projected to reach $47 billion to $53 billion by 2030, while it continues advancing its SPC-15 PTSD program toward an investigational new drug application submission and Phase 1 clinical trials, underscoring a dual focus on biopharmaceutical development and emerging AI-driven revenue opportunities.
According to the press release available at https://ibn.fm/XJG64, Silo Pharma is a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company. Its therapeutic focus is on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system diseases. The company’s portfolio includes innovative programs such as SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer’s disease and multiple sclerosis. Silo’s research is conducted in collaboration with leading universities and laboratories.
The acquisition of Qwikagents.ai allows Silo to enter the AI agent market, which is expected to grow significantly through the end of the decade. Autonomous AI agents represent a new frontier in automation, capable of performing complex tasks without human intervention. This move diversifies Silo’s revenue streams beyond its core biopharmaceutical operations, which have yet to generate commercial products. The company’s biotech pipeline remains focused on central nervous system disorders, with SPC-15 for PTSD being its most advanced program. The AI business is expected to provide near-term revenue while the biotech assets progress through clinical development.
Silo Pharma also maintains a cryptocurrency treasury, adding another layer of financial strategy. The company’s newsroom, accessible at https://ibn.fm/SILO, provides updates on its activities. The expansion into AI reflects a broader trend of biotech firms seeking alternative revenue sources amid the high costs and long timelines of drug development. By leveraging the Qwikagents platform, Silo aims to offer AI-driven automation services to businesses, potentially generating cash flow to support its research programs.
The announcement underscores Silo’s strategic pivot to capitalize on the AI boom while maintaining its commitment to developing therapies for underserved medical conditions. The dual focus may appeal to investors seeking exposure to both high-growth AI and biotech sectors. However, the success of this strategy depends on Silo’s ability to execute in two distinct industries, each with its own competitive and regulatory challenges.
